Nektar Therapeutics (NASDAQ:NKTR) has been assigned a $33.00 price objective by equities researchers at Roth Capital in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s target price indicates a potential upside of 76.66% from the stock’s previous close.

Other equities research analysts have also issued research reports about the stock. Jefferies Group LLC decreased their price target on shares of Nektar Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Wednesday, May 10th. Aegis reiterated a “buy” rating and issued a $27.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday, May 10th. BidaskClub upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, August 1st. Finally, HC Wainwright initiated coverage on shares of Nektar Therapeutics in a research note on Monday. They issued a “buy” rating and a $31.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $26.78.

Shares of Nektar Therapeutics (NKTR) opened at 18.68 on Wednesday. The stock’s 50 day moving average price is $20.64 and its 200-day moving average price is $18.29. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.88. The company’s market cap is $2.90 billion.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. Nektar Therapeutics had a negative return on equity of 965.21% and a negative net margin of 157.14%. The company had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. During the same quarter in the previous year, the business earned ($0.36) EPS. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, analysts expect that Nektar Therapeutics will post ($1.02) EPS for the current year.

WARNING: “Nektar Therapeutics (NKTR) Given a $33.00 Price Target by Roth Capital Analysts” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/nektar-therapeutics-nktr-given-a-33-00-price-target-by-roth-capital-analysts/1468290.html.

In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 45,080 shares of the firm’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $21.08, for a total value of $950,286.40. Following the completion of the transaction, the senior vice president now directly owns 51,961 shares of the company’s stock, valued at approximately $1,095,337.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Stephen K. Doberstein sold 1,701 shares of the firm’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $19.55, for a total transaction of $33,254.55. Following the completion of the transaction, the senior vice president now directly owns 32,803 shares of the company’s stock, valued at $641,298.65. The disclosure for this sale can be found here. Insiders sold a total of 159,803 shares of company stock valued at $3,328,247 over the last quarter. 6.10% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Flinton Capital Management LLC increased its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 448 shares during the last quarter. First Trust Advisors LP increased its position in shares of Nektar Therapeutics by 8.0% in the first quarter. First Trust Advisors LP now owns 2,249,950 shares of the biopharmaceutical company’s stock valued at $52,806,000 after buying an additional 166,521 shares during the last quarter. Great West Life Assurance Co. Can increased its position in shares of Nektar Therapeutics by 7.0% in the first quarter. Great West Life Assurance Co. Can now owns 213,944 shares of the biopharmaceutical company’s stock valued at $5,019,000 after buying an additional 13,956 shares during the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Nektar Therapeutics by 16.9% in the first quarter. Tocqueville Asset Management L.P. now owns 234,402 shares of the biopharmaceutical company’s stock valued at $5,501,000 after buying an additional 33,850 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Nektar Therapeutics by 7.4% in the first quarter. Wells Fargo & Company MN now owns 207,320 shares of the biopharmaceutical company’s stock valued at $4,866,000 after buying an additional 14,202 shares during the last quarter. 94.09% of the stock is owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.